Amgen Inc. (NASDAQ:AMGN) – Amgen’s Tezspire Reduces Annualized Exacerbation Rate in Patients With Severe Asthma

Amgen Inc. (NASDAQ: AMGN) has shared the results of a pooled post-hoc analysis of the NAVIGATOR Phase 3 and PATHWAY Phase 2b trials of Tezspire (tezepelumab-ekko) in a large population of asthma patients.

• Tezspire is indicated for the additional maintenance treatment of adult and pediatric patients aged 12 years and over with severe asthma.
• In the pooled analysis, Tezspire, when added to the standard of care (SoC), reduced asthma exacerbations in patients regardless of baseline blood eosinophil count, demonstrating consistent efficacy with 71%, 48% and 48% over 52 weeks, compared to placebo added to the SoC.
• Also see: Amgen releases latest batch of Lumakras pancreatic cancer data.
• In the same analysis, Tezspire also demonstrated improvements in AAER in patients regardless of fractionated exhaled nitric oxide (FeNO) level and allergic status over 52 weeks, compared to placebo.
• In a predefined NAVIGATOR exploratory analysis, Tezspire showed consistent efficacy throughout the year, regardless of season.
• The proportion of patients with an exacerbation was lower in the Tezspire group than in the placebo group in all seasons.
• Price action: AMGN shares closed up 3.54% at $227.03 on Friday.